Maia Wealth LLC Purchases Shares of 14,396 ImmunityBio, Inc. (NASDAQ:IBRX)

Maia Wealth LLC purchased a new stake in ImmunityBio, Inc. (NASDAQ:IBRX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 14,396 shares of the company’s stock, valued at approximately $37,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. State Street Corp increased its position in shares of ImmunityBio by 10.1% during the third quarter. State Street Corp now owns 8,654,460 shares of the company’s stock worth $32,195,000 after purchasing an additional 790,408 shares in the last quarter. Barclays PLC increased its position in shares of ImmunityBio by 127.4% during the third quarter. Barclays PLC now owns 361,036 shares of the company’s stock worth $1,344,000 after purchasing an additional 202,248 shares in the last quarter. Stephens Inc. AR acquired a new stake in shares of ImmunityBio during the fourth quarter worth about $26,000. HighTower Advisors LLC acquired a new stake in shares of ImmunityBio during the third quarter worth about $136,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of ImmunityBio by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock worth $99,000 after purchasing an additional 4,545 shares in the last quarter. 8.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. D. Boral Capital reiterated a “buy” rating and set a $30.00 target price on shares of ImmunityBio in a research report on Friday. BTIG Research assumed coverage on ImmunityBio in a research report on Friday, January 10th. They set a “buy” rating and a $6.00 target price on the stock.

ImmunityBio Stock Down 13.4 %

Shares of IBRX stock opened at $2.85 on Tuesday. The stock has a market capitalization of $1.99 billion, a PE ratio of -3.10 and a beta of 0.94. ImmunityBio, Inc. has a 52-week low of $2.28 and a 52-week high of $10.53. The stock’s 50-day moving average price is $3.02 and its 200 day moving average price is $3.73.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.11. Analysts expect that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.